SlideShare a Scribd company logo
Plan evaluation: Lung Cancers
Dr. Ashutosh Mukherji
Additional Professor,
Department of Radiotherapy,
Regional Cancer Centre,
and Associate Dean (Research), JIPMER
Target Volumes
• Radiotherapy alone affords intrathoracic control in
up to 50% of NSCLC cases, provided a total dose > 60
Gy is employed
• For many years, standard RT practice was:
– 40 to 50 Gy to the electively irradiated regional-nodal
areas
– Additional 10-20 Gy delivered to the primary tumor
through reduced fields.
Lung cancer radiotherapy
• RT for lung cancer getting increasingly sophisticated
• Usually addition of concurrent chemotherapy in
radical treatment of locally advanced tumours
• Side effects tend to increase with poor lung function
patients and addition of chemotherapy.
• Need to identify parameters to preempt / reduce
toxicity
• V 20 and V 5 are two such parameters
RT-Planning – Definition of Target Volumes
ICRU 50 + 62
Gross Tumour Volume
Clinical Target Volume
Planning Target Volume
CT: standard imaging modality
Complementary information by MRI and PET scanning
Limiting factors of CT imaging for lung cancer:
-planning-CT without intravenous contrast so as not to
disturb
the electron density information
interpretation always in conjunction with diagnostic CT
-not routinely possible to distinguish T3 – T4
(MRI some advantages)
-MRI used for imaging apical primary tumours
(Pancoast)
-Sensitivity / specificity only 60 / 77% for LN
knowledge of normal anatomy (LN levels, hilar anatomy) !
knowledge of patterns of lymphatic drainage
RT-Planning – Defining the GTV
Integrating PET
Value of PET for PT:
Atelectasis – reduction of
irradiated volume
Value of PET for LN staging:
Sensitivity 79%
Specificity 91%
Negative predictive value 95%
Positive predictive value 80%
(hot spots still require
verification)
Value of PET for Metastases:
metastases detected in10-15%
of surgical candidates
Impact of PET on RT planning
PTV increased in 64% (detected
nodes)
decreased in 36% (exclusion of
atelectasis)
(Erdi 2002)
Average reduction of PTV by 29%
Average reduction of V20 by 27%
(Vanuytsel 2000)
Interobserver variability reduced:
mean ratio of GTV without PET:
2.31
mean ratio of GTV with PET:
1.56
(Caldwell 2001)
RT-Planning –
Defining the GTV
Impact of PET: PTV
RT-Planning – Defining the GTV
Limiting factors of PET
-Resolution 4-8mm (depending on scanner and institution)
-Registration errors (esp. with software based fusion)
-Threshold value (SUV) individually to be determined
Summary:
PET is a promising complementary tool in RT planning of NSCLC.
Its value for staging has been established and preliminary
reports suggest that it may lead to more consistent definition of
GTV in RT planning. However, it is still not clear, whether this will
translate into better survival.
RT-Planning – Defining the CTV
1. Margin around primary tumour (microscopic spread)
Histopathologic quantification of subclinical cancer around the grossly visible primary
(Giraud 2000):
Microscopic extension Adeno Squamos
mean value 2.69mm 1.48mm
5mm margin covers: 80% 91%
margin to cover 95% 8mm 6mm
This data could also be used for IMRT planning:
-define constraint for GTV (dose escalation to primary)
-define constraint for subclinical disease (less dose)
-increase therapeutic index
RT-Planning – Defining the CTV
2. Subclinical lymph nodes (ENI)
-high risk of nodal spread in lung cancer
-but value of ENI is not proven
Reasons against ENI:
-less than 20% locally controlled 1y after RT with conventional
dose (Arriagada 1991)
-need for more intense treatment to gross tumour
-large volumes prevent dose escalation (normal tissue tolerance)
-small primary tumor and small total tumor volume predictive
(Basaki 2006, RTOG 93-11 2008)
-modern chemotherapy regimens may lead to better control of
microscopic disease
?? Elective Nodal Irradiation ??
• The rationale against elective nodal irradiation
is the high local recurrence rates and the high
chance of distant metastasis.
• A series of 171 patients treated definitively
with 3DCRT to only involved field volumes.
• 6.4% of patients suffered elective nodal
failures
Why the less than expected nodal
recurrence?
• Incidental doses to the ipsilateral hilum,
paratracheal, and subcarinal nodes approach
40 to 50 Gy
• Patients may die of local failure, distant
failure, or intercurrent illness without
detection of elective nodal failures.
RT-Planning – Defining the CTV
2. Subclinical lymph nodes (ENI)
From large ....
“Old“ Standard … (Perez 1997)
RT-Planning – Defining the CTV
2. Subclinical lymph nodes (ENI)
.... to small !
…“New“ Trend (IMRT 2007)
RT-Planning – Defining the PTV
ICRU recommendations
CTV ...
+ Internal Margin (Internal Target Volume)
variations in position, size and shape of CTV
(internal reference system
attached to the patient)
+ Set-up Margin
variations in relation patient - beam
(external reference system
attached to machine)
RT-Planning – Defining the PTV
Reducing set-up uncertainty:
-Daily EPID: -matching DRR - EPI
-distinguish between systematic (needs correction)
and random error (no correction needed)
RT-Planning – Defining the PTV
Reducing respiration induced
errors:
Size of movement dependent on:
- tumour location in the lung
- fixation to adjacent structures
- lung capacity and oxygenation
- patient fixation and anxiety
Steppenwoolde 2004
Reducing respiration induced errors:
-Breath - hold
-Voluntary (Deep Inspiration Breath Hold)
-Forced (Active Breathing Control)
-CT scanning
-Slow scanning
-Respiration correlated CT
-Gating
Average movement in normal breathing:
- Upper lobe 0 - 0.5cm
- Lower lobe 1.5 - 4.0cm
- Middle lobe 0.5 - 2.5cm
- Hilum 1.0 - 1.5cm
RT-Planning – Defining the PTV
Reducing respiration induced errors:
Gated CT normally
reduces the margin
PTV - CTV
(compared to using
published data):
RT-Planning – Defining the PTV
Drawing PTV in gated planning CT:
-Define GTV/CTV for inspiration and expiration phase
-Give a margin of 0.5 - 1cm in all directions (setup uncertainty)
DON’T use dose escalation and highly conformal techniques
such as IMRT for lung cancer until tumour motion can be taken
into account !
In the meantime ...
-Outline GTV as best as possible
-Construct CTV based on the literature
-Construct PTV based on measured tumour motion and known
setup uncertainty.
ERS 2009
19
The risk of developing radiation pneumonitis-induced
lung toxicity can be estimated by calculating the dose–
volume histogram of the lungs, including V20 and mean
lung dose (MLD)
V 20
“V20”
Percentage of the lung volume which receives
radiation doses of 20 Gy or more.
(with subtraction of the vol involved by lung cancer
- PTV)
The risk for radiation pneumonitis depends on V20
V20 = 22% risk for radiation pneumonitis is nearly zero.
V 20 = 33% radiation induced pneumonitis is 10 -15%
V20 of 35%, 40% - radiation pneumonitis nearly 50%.
PhaseI/II
Stage 1-3
unresectable
3DCRT, 2.15Gy fr
Group1
V20Gy<25%:
70.9Gy/33frs to
90.3Gy/42frs
Group2
V20Gy – 25-36%:
70.9Gy/33frs to
77.4Gy/36frs
Group 3:
V20>37%
Closed early
RTOG 9311: Trial Schema
179 pts
RTOG 9311 : Conclusions
• RT dose was safely escalated using the 3D CRT
• 83.8 Gy for pts with V20 values of <25% Grp I,
• 77.4 Gy for pts with V20 values 25% - 36% Grp 2,
• The 90.3 Gy dose was too toxic (deaths 2 pts)
• Using fraction size of 2.15 Gy.
• Elective nodal failure occurred in <10 pts
Jafrey Badley IJRBP vol 61, No 2, 318-328, 2005
Volumes while contouring lung as
OAR
• Need to select the optimal CT window settings
(Lung window)
• W = 1600 and C=-600 for parenchyma
• Contour each lung separately
• Contour GTV, CTV and PTV
• Using Boolean function , generate lung OAR
• Lung OAR= (Left lung + Right Lung) - PTV
Dose/Volume constraints
Kong et al, IJROBP, 2010
Basic Definitions
• V 20 = Volume of (B/L lung – PTV) receiving 20 Gray OR MORE
Total volume of B/L Lung – PTV
(represents intermediate dose area)
• V 5 = Volume of (B/L lung – PTV) receiving 5 Gray OR MORE
Total volume of B/L Lung – PTV
(represents low dose area)
Normal tissue constraints for Lung
V 20 <35%
V 5 < 60%
V 5
• Represents area of lung receiving low /very low dose
RT
• Gained in importance in IMRT era
• Especially important in techniques such as VMAT and
Tomotherapy which give rotational therapies
• Another way to emphasising that low dose areas
with IMRT are as equally important.
27
V5
28
V5 opposite lung
V5 treated lung
Seminal Publication – V 20
Graham MV, Purdy JA, Emami B, et al. Clinical dose-
volume histogram analysis for pneumonitis after 3D
treatment for non-smallcell lung cancer (NSCLC).
Int J Radiat Oncol Biol Phys 1999;45:323-329.
30
V20
31
V20 opposite lung
V20 treated lung
Elevated V 20 and V 5
• Truly elevated V 20 and V 5
– Large PTV
– Poor planning
• Spurious elevation of V 20 and V 5
– Lung not contoured properly (portions left out)
– Incorrect window used
– PTV not subtracted out from bilateral lungs
Means to reduce V 20 (3D CRT)
– Need to have a good measure of tumour location and
likely volumes
– Lower lobe tumours likely to have worse dosimetric
parameters
– Need to place appropriate beams(beam angles, number)
– Special arrangements in specific tumour positions
Means to reduce V 20
• Use IMRT instead of 3 DCRT in appropriate cases
• Use of advanced strategies like gating/tracking/breath
hold (it shall decrease the PTV and thereby decrease the
zone that get 20 Gray)
• Use of ABC device
– PTV smaller
– Simulation and treatment in inspiratory position
– Lungs inflated
– Lung volume increases and hence denominator more, V 20
falls
• 41 patients of NSCLC
• 3 D CRT and IMRT plans(9 F, equidistant, coplanar, generated)
• Target, isocentre and prescription same as 3 D CRT
Murshed, IJROBP, 2003V 10 and V20 reduced by 7% and 10% respectively
IGRT- 4 D aspects
• Further ensuring the Planned dose and the treatment dose similarity
• Removal of motion encompassing margins may reduce normal tissue dose
• Reduction in normal tissue dose may facilitate tumour dose escalation
• Higher doses delivered to the tumour could result in an improved cure
rate
Individualised
Motion Margin
Setup &
Equipment Margins
Clinical Target
Volume
Planning Target Volume
Residual Error
Margins
Clinical Target
Volume
Target tracking Treatments
Conventional With gated imaging
Effect of Gated/4 D imaging
Tumor
Keall et al Aust Phys Eng Sci Med 2002
ABC
• Device holds the patients breath in a
particular phase of respiration
• Usually the mDIBH level chosen – 70%to
80% of maximum inspiratory capacity
• Suitable breath hold duration chosen –
commonly 20 to 25 seconds
ABC
• CT scan acquired (approx two breath
holds required to scan the thorax/breast
area)
• Treatment planning and
execution(4-6 breath holds per
treatment)
ABC outcomes
• 18 NSCLC patients from RMH , UK
• Mean reduction in GTV 25% (p= 0.003).
• Compared with free-breathing, ABC reduced
• V(20) by 13% (p=0.0001)
• V(13) by 12% (p=0.001)
• MLD by 13% (p<0.001)
Brada et al IJROBP 2010
Outcomes of Respiratory Gating
• Twenty patients with CT under assisted breath
hold at normal inspiration, at full expiration
and under free breathing
• 13 of 20 patients had GTVs of <100 cm3
• Benefit of V20 reduction only with small
tumours (volume of GTV < 100 cm3) and
significant tumour motion
Starkschall IJROBP 2004
Caution!
• V20 and V5 could vary from one planning workstation to
another
• Different algorithms may yield variable V 20 and V 5
(Batho, Monte Carlo algorithm)
• Algorithms can be especially important as there is
variation in lung density.
• Algorithms derived directly from Monte Carlo, such as
superposition-convolution and collapsed cone far
superior to algorithms of the past (e.g. the one used in
seminal publication)
Drawbacks of V 20/ V 5
• DVH represents anatomic pulmonary volume, which
does not reflect a variety of confounding factors.
• Not a functional parameter (does not take into
account lung function)
• Several other factors important in radiation
pneumonitis and need to be accounted
(PS,concurrent chemo, smoking, age, ….)
45
V30 opposite lung
V30 treated lung
46
Global Dmax location
Target volume Dmax
location
Vdmax
QA…… Fluence analyses showed
most planned cases treatable
with ≥ 95% fidelity
47
Summary / Conclusions
• V 5 and V 20 are important parameters to see and
evaluate during radical radiotherapy of lung cancer
• V30 and VDmax also need to be seen.
• For IMRT plans PTV cover and contouring should take
into account tumour movement
• Be cognizant of the pitfalls of these parameters as
well
• See totality of patient / tumour / dosimetric
parameters and not one or two factors in isolation
Summary planning Recommendations - EORTC
• 3-D radiotherapy planning is essential for ensuring optimal both
target coverage and the sparing of normal tissues.
• 3D margins for the PTV based on institutional random and
systematic errors and tumour movement
• Margins required for microscopic tumour extension in
radiotherapy planning of NSCLC are approximately 5-6 mm.
• Risk of radiation pneumonitis can be estimated from the V20
(volume of both lungs minus the PTV which receives a dose of 20
Gy), and by the mean lung dose.
• Incorporating FDG-PET findings into CT-based planning scan
results in changes to radiotherapy plans in a significant proportion
of patients.
49
THANK YOU
51

More Related Content

What's hot

APBI-Dr Kiran
APBI-Dr Kiran APBI-Dr Kiran
APBI-Dr Kiran
Kiran Ramakrishna
 
Contouring guidelines Cervix IMRT
Contouring guidelines Cervix IMRTContouring guidelines Cervix IMRT
Contouring guidelines Cervix IMRT
Debarshi Lahiri
 
SBRT Contouring Guidelines
SBRT  Contouring  GuidelinesSBRT  Contouring  Guidelines
SBRT Contouring Guidelines
Dr Rushi Panchal
 
Rrecent advances in linear accelerators [MR linac]
Rrecent advances in linear accelerators [MR linac]Rrecent advances in linear accelerators [MR linac]
Rrecent advances in linear accelerators [MR linac]
Upasna Saxena
 
TARGET DELINEATION OF CANCER ESOPHAGUS
TARGET DELINEATION OF CANCER ESOPHAGUSTARGET DELINEATION OF CANCER ESOPHAGUS
TARGET DELINEATION OF CANCER ESOPHAGUS
Kanhu Charan
 
ICRU 89 summary & beyond converted
ICRU 89 summary & beyond convertedICRU 89 summary & beyond converted
ICRU 89 summary & beyond converted
Dr. Abhishek Basu
 
Rt techniques in lymphoma
Rt techniques in lymphomaRt techniques in lymphoma
Rt techniques in lymphoma
Kiran Ramakrishna
 
Approach towards reirradiation
Approach towards reirradiationApproach towards reirradiation
Approach towards reirradiation
Kanhu Charan
 
Hemi body irradiation
Hemi body irradiationHemi body irradiation
Hemi body irradiation
Nilesh Kucha
 
ICRU CONCEPT
ICRU CONCEPTICRU CONCEPT
ICRU CONCEPT
Kanhu Charan
 
LUNG SBRT A LITERATURE REVIEW
LUNG SBRT A LITERATURE REVIEWLUNG SBRT A LITERATURE REVIEW
LUNG SBRT A LITERATURE REVIEW
Kanhu Charan
 
Radiotherapy planning for rectal cancer ,2D updates!
Radiotherapy planning for rectal cancer ,2D   updates!Radiotherapy planning for rectal cancer ,2D   updates!
Radiotherapy planning for rectal cancer ,2D updates!
Gebrekirstos Hagos Gebrekirstos, MD
 
IMRT and 3D CRT in cervical Cancers
IMRT and 3D CRT in cervical CancersIMRT and 3D CRT in cervical Cancers
IMRT and 3D CRT in cervical Cancers
Santam Chakraborty
 
Contouring rectal cancers
Contouring rectal cancersContouring rectal cancers
Contouring rectal cancers
Ashutosh Mukherji
 
Breast contouring and planning techniques
Breast contouring and planning techniquesBreast contouring and planning techniques
Breast contouring and planning techniques
Rituraj Upadhyay
 
ABC system, Free Breath 4DCT & Symmetry Radiotherapy
ABC system, Free Breath 4DCT & Symmetry RadiotherapyABC system, Free Breath 4DCT & Symmetry Radiotherapy
ABC system, Free Breath 4DCT & Symmetry Radiotherapy
Sanjeet Mandal
 
Icru 58.
Icru 58.Icru 58.
Icru 58.
anju k.v.
 
Hippocampal sparing whole brain radiation therapy- Making a case!
Hippocampal sparing  whole brain radiation therapy- Making a case!Hippocampal sparing  whole brain radiation therapy- Making a case!
Hippocampal sparing whole brain radiation therapy- Making a case!
VIMOJ JANARDANAN NAIR
 
Lung sbrt ppt
Lung  sbrt pptLung  sbrt ppt
Lung sbrt ppt
Dr. Rituparna Biswas
 

What's hot (20)

APBI-Dr Kiran
APBI-Dr Kiran APBI-Dr Kiran
APBI-Dr Kiran
 
Contouring guidelines Cervix IMRT
Contouring guidelines Cervix IMRTContouring guidelines Cervix IMRT
Contouring guidelines Cervix IMRT
 
SBRT Contouring Guidelines
SBRT  Contouring  GuidelinesSBRT  Contouring  Guidelines
SBRT Contouring Guidelines
 
Rrecent advances in linear accelerators [MR linac]
Rrecent advances in linear accelerators [MR linac]Rrecent advances in linear accelerators [MR linac]
Rrecent advances in linear accelerators [MR linac]
 
TARGET DELINEATION OF CANCER ESOPHAGUS
TARGET DELINEATION OF CANCER ESOPHAGUSTARGET DELINEATION OF CANCER ESOPHAGUS
TARGET DELINEATION OF CANCER ESOPHAGUS
 
ICRU 89 summary & beyond converted
ICRU 89 summary & beyond convertedICRU 89 summary & beyond converted
ICRU 89 summary & beyond converted
 
Rt techniques in lymphoma
Rt techniques in lymphomaRt techniques in lymphoma
Rt techniques in lymphoma
 
Approach towards reirradiation
Approach towards reirradiationApproach towards reirradiation
Approach towards reirradiation
 
Hemi body irradiation
Hemi body irradiationHemi body irradiation
Hemi body irradiation
 
ICRU CONCEPT
ICRU CONCEPTICRU CONCEPT
ICRU CONCEPT
 
LUNG SBRT A LITERATURE REVIEW
LUNG SBRT A LITERATURE REVIEWLUNG SBRT A LITERATURE REVIEW
LUNG SBRT A LITERATURE REVIEW
 
Radiotherapy planning for rectal cancer ,2D updates!
Radiotherapy planning for rectal cancer ,2D   updates!Radiotherapy planning for rectal cancer ,2D   updates!
Radiotherapy planning for rectal cancer ,2D updates!
 
ICRU 38 nayana
ICRU 38 nayanaICRU 38 nayana
ICRU 38 nayana
 
IMRT and 3D CRT in cervical Cancers
IMRT and 3D CRT in cervical CancersIMRT and 3D CRT in cervical Cancers
IMRT and 3D CRT in cervical Cancers
 
Contouring rectal cancers
Contouring rectal cancersContouring rectal cancers
Contouring rectal cancers
 
Breast contouring and planning techniques
Breast contouring and planning techniquesBreast contouring and planning techniques
Breast contouring and planning techniques
 
ABC system, Free Breath 4DCT & Symmetry Radiotherapy
ABC system, Free Breath 4DCT & Symmetry RadiotherapyABC system, Free Breath 4DCT & Symmetry Radiotherapy
ABC system, Free Breath 4DCT & Symmetry Radiotherapy
 
Icru 58.
Icru 58.Icru 58.
Icru 58.
 
Hippocampal sparing whole brain radiation therapy- Making a case!
Hippocampal sparing  whole brain radiation therapy- Making a case!Hippocampal sparing  whole brain radiation therapy- Making a case!
Hippocampal sparing whole brain radiation therapy- Making a case!
 
Lung sbrt ppt
Lung  sbrt pptLung  sbrt ppt
Lung sbrt ppt
 

Similar to Lung plan evaluation

ICRU REPORT 50 and 62.pptx
ICRU REPORT 50 and 62.pptxICRU REPORT 50 and 62.pptx
ICRU REPORT 50 and 62.pptx
ssuser694481
 
RT in Ca esophagus
RT in Ca esophagusRT in Ca esophagus
RT in Ca esophagus
Dr.Rashmi Yadav
 
ICRU reports 50 and 62
ICRU reports 50 and 62ICRU reports 50 and 62
ICRU reports 50 and 62
Bharti Devnani
 
Radiotherapy in ca esophagus
Radiotherapy in ca esophagusRadiotherapy in ca esophagus
Radiotherapy in ca esophagus
Isha Jaiswal
 
Radiation Therapy in the Management of Lung Cancer
Radiation Therapy in the Management of Lung CancerRadiation Therapy in the Management of Lung Cancer
Radiation Therapy in the Management of Lung Cancer
flasco_org
 
Imrt&amp;vmat
Imrt&amp;vmatImrt&amp;vmat
Imrt&amp;vmat
HEBAGOMAA1984
 
Radiotherapy Planning For Esophageal Cancers
Radiotherapy Planning For Esophageal CancersRadiotherapy Planning For Esophageal Cancers
Radiotherapy Planning For Esophageal Cancersfondas vakalis
 
1411 APLCC AHNYC SBRT & IMRT in Lung Cancer
1411 APLCC AHNYC SBRT & IMRT in Lung Cancer1411 APLCC AHNYC SBRT & IMRT in Lung Cancer
1411 APLCC AHNYC SBRT & IMRT in Lung Cancer
Yong Chan Ahn
 
Radiotherapy contouring guideline for non-hodgkin lymphoma
Radiotherapy contouring guideline for non-hodgkin lymphomaRadiotherapy contouring guideline for non-hodgkin lymphoma
Radiotherapy contouring guideline for non-hodgkin lymphoma
ketan kalariya
 
Prostate
ProstateProstate
Prostate
Parneet Singh
 
Overview of ART in lung cancer
Overview of ART in lung cancerOverview of ART in lung cancer
Overview of ART in lung cancer
Naveen Mummudi
 
Lungs contouring Dr. Abani.pdf
Lungs contouring Dr. Abani.pdfLungs contouring Dr. Abani.pdf
Lungs contouring Dr. Abani.pdf
Dr. Abani Kanta Nanda
 
sublobar resection.pptx
sublobar resection.pptxsublobar resection.pptx
sublobar resection.pptx
KevinLim533467
 
Random and systematic errors 25.10.12
Random and systematic errors 25.10.12Random and systematic errors 25.10.12
Random and systematic errors 25.10.12
Gemelli Advanced Radiation Therapy
 
Lung cancer
Lung cancerLung cancer
Lung cancer
Gurneet Singh
 
Management of lung cancer
Management of lung cancerManagement of lung cancer
Management of lung cancer
Nilaxi Khataniar
 
Post Mastectomy Radiotherapy
Post Mastectomy RadiotherapyPost Mastectomy Radiotherapy
Post Mastectomy Radiotherapyfondas vakalis
 
Extended field Radiotherapy with chemotherapy in treatment of cervical carcin...
Extended field Radiotherapy with chemotherapy in treatment of cervical carcin...Extended field Radiotherapy with chemotherapy in treatment of cervical carcin...
Extended field Radiotherapy with chemotherapy in treatment of cervical carcin...
subhas123
 
Ca Cervix Dr Naresh Jakhotia
Ca Cervix Dr Naresh JakhotiaCa Cervix Dr Naresh Jakhotia
Ca Cervix Dr Naresh Jakhotia
drnareshjakhotia
 

Similar to Lung plan evaluation (20)

Iort
IortIort
Iort
 
ICRU REPORT 50 and 62.pptx
ICRU REPORT 50 and 62.pptxICRU REPORT 50 and 62.pptx
ICRU REPORT 50 and 62.pptx
 
RT in Ca esophagus
RT in Ca esophagusRT in Ca esophagus
RT in Ca esophagus
 
ICRU reports 50 and 62
ICRU reports 50 and 62ICRU reports 50 and 62
ICRU reports 50 and 62
 
Radiotherapy in ca esophagus
Radiotherapy in ca esophagusRadiotherapy in ca esophagus
Radiotherapy in ca esophagus
 
Radiation Therapy in the Management of Lung Cancer
Radiation Therapy in the Management of Lung CancerRadiation Therapy in the Management of Lung Cancer
Radiation Therapy in the Management of Lung Cancer
 
Imrt&amp;vmat
Imrt&amp;vmatImrt&amp;vmat
Imrt&amp;vmat
 
Radiotherapy Planning For Esophageal Cancers
Radiotherapy Planning For Esophageal CancersRadiotherapy Planning For Esophageal Cancers
Radiotherapy Planning For Esophageal Cancers
 
1411 APLCC AHNYC SBRT & IMRT in Lung Cancer
1411 APLCC AHNYC SBRT & IMRT in Lung Cancer1411 APLCC AHNYC SBRT & IMRT in Lung Cancer
1411 APLCC AHNYC SBRT & IMRT in Lung Cancer
 
Radiotherapy contouring guideline for non-hodgkin lymphoma
Radiotherapy contouring guideline for non-hodgkin lymphomaRadiotherapy contouring guideline for non-hodgkin lymphoma
Radiotherapy contouring guideline for non-hodgkin lymphoma
 
Prostate
ProstateProstate
Prostate
 
Overview of ART in lung cancer
Overview of ART in lung cancerOverview of ART in lung cancer
Overview of ART in lung cancer
 
Lungs contouring Dr. Abani.pdf
Lungs contouring Dr. Abani.pdfLungs contouring Dr. Abani.pdf
Lungs contouring Dr. Abani.pdf
 
sublobar resection.pptx
sublobar resection.pptxsublobar resection.pptx
sublobar resection.pptx
 
Random and systematic errors 25.10.12
Random and systematic errors 25.10.12Random and systematic errors 25.10.12
Random and systematic errors 25.10.12
 
Lung cancer
Lung cancerLung cancer
Lung cancer
 
Management of lung cancer
Management of lung cancerManagement of lung cancer
Management of lung cancer
 
Post Mastectomy Radiotherapy
Post Mastectomy RadiotherapyPost Mastectomy Radiotherapy
Post Mastectomy Radiotherapy
 
Extended field Radiotherapy with chemotherapy in treatment of cervical carcin...
Extended field Radiotherapy with chemotherapy in treatment of cervical carcin...Extended field Radiotherapy with chemotherapy in treatment of cervical carcin...
Extended field Radiotherapy with chemotherapy in treatment of cervical carcin...
 
Ca Cervix Dr Naresh Jakhotia
Ca Cervix Dr Naresh JakhotiaCa Cervix Dr Naresh Jakhotia
Ca Cervix Dr Naresh Jakhotia
 

More from Ashutosh Mukherji

Mgmt vulva and vagina cancers
Mgmt vulva and vagina cancersMgmt vulva and vagina cancers
Mgmt vulva and vagina cancers
Ashutosh Mukherji
 
High risk early stage ec
High risk early stage ecHigh risk early stage ec
High risk early stage ec
Ashutosh Mukherji
 
Radiotherapy sarcomas
Radiotherapy sarcomas Radiotherapy sarcomas
Radiotherapy sarcomas
Ashutosh Mukherji
 
Debate: CCRT in Pancreatic cancer
Debate: CCRT in Pancreatic cancerDebate: CCRT in Pancreatic cancer
Debate: CCRT in Pancreatic cancer
Ashutosh Mukherji
 
Rectal cancer debate: Chemoradiation
Rectal cancer debate: ChemoradiationRectal cancer debate: Chemoradiation
Rectal cancer debate: Chemoradiation
Ashutosh Mukherji
 
Role of Post-op Radiotherapy in Head and Neck Cancers
Role of Post-op Radiotherapy in Head and Neck CancersRole of Post-op Radiotherapy in Head and Neck Cancers
Role of Post-op Radiotherapy in Head and Neck Cancers
Ashutosh Mukherji
 
Sarcoma brachytherapy updates
Sarcoma brachytherapy updatesSarcoma brachytherapy updates
Sarcoma brachytherapy updates
Ashutosh Mukherji
 
Crc rt updates ethiopia
Crc rt updates   ethiopiaCrc rt updates   ethiopia
Crc rt updates ethiopia
Ashutosh Mukherji
 
Icru 71 electrons
Icru 71 electrons Icru 71 electrons
Icru 71 electrons
Ashutosh Mukherji
 
Hypofractionation in hnc
Hypofractionation in hncHypofractionation in hnc
Hypofractionation in hnc
Ashutosh Mukherji
 
Nasopharyngeal brachytherapy
Nasopharyngeal brachytherapyNasopharyngeal brachytherapy
Nasopharyngeal brachytherapy
Ashutosh Mukherji
 
Biomarkers in gliomas
Biomarkers in gliomasBiomarkers in gliomas
Biomarkers in gliomas
Ashutosh Mukherji
 
Screening in colorectal cancers dr. ashutosh
Screening in colorectal cancers  dr. ashutoshScreening in colorectal cancers  dr. ashutosh
Screening in colorectal cancers dr. ashutosh
Ashutosh Mukherji
 
Gastric cancer contouring panel discussion, icc 2017
Gastric cancer contouring panel discussion, icc 2017Gastric cancer contouring panel discussion, icc 2017
Gastric cancer contouring panel discussion, icc 2017
Ashutosh Mukherji
 
Srs debate dr. ashutosh mukherji
Srs debate   dr. ashutosh mukherjiSrs debate   dr. ashutosh mukherji
Srs debate dr. ashutosh mukherji
Ashutosh Mukherji
 
IMRT in pancreas
IMRT in pancreasIMRT in pancreas
IMRT in pancreas
Ashutosh Mukherji
 
Stomach adjuvant rt
Stomach adjuvant rtStomach adjuvant rt
Stomach adjuvant rt
Ashutosh Mukherji
 
IHC in breast CA
IHC in breast CAIHC in breast CA
IHC in breast CA
Ashutosh Mukherji
 
Radiotherapy in paediatrics - late effects and second malignancies
Radiotherapy in paediatrics - late effects and second malignanciesRadiotherapy in paediatrics - late effects and second malignancies
Radiotherapy in paediatrics - late effects and second malignancies
Ashutosh Mukherji
 
Personalised medicine in rt dr. ashutosh
Personalised medicine in rt   dr. ashutoshPersonalised medicine in rt   dr. ashutosh
Personalised medicine in rt dr. ashutosh
Ashutosh Mukherji
 

More from Ashutosh Mukherji (20)

Mgmt vulva and vagina cancers
Mgmt vulva and vagina cancersMgmt vulva and vagina cancers
Mgmt vulva and vagina cancers
 
High risk early stage ec
High risk early stage ecHigh risk early stage ec
High risk early stage ec
 
Radiotherapy sarcomas
Radiotherapy sarcomas Radiotherapy sarcomas
Radiotherapy sarcomas
 
Debate: CCRT in Pancreatic cancer
Debate: CCRT in Pancreatic cancerDebate: CCRT in Pancreatic cancer
Debate: CCRT in Pancreatic cancer
 
Rectal cancer debate: Chemoradiation
Rectal cancer debate: ChemoradiationRectal cancer debate: Chemoradiation
Rectal cancer debate: Chemoradiation
 
Role of Post-op Radiotherapy in Head and Neck Cancers
Role of Post-op Radiotherapy in Head and Neck CancersRole of Post-op Radiotherapy in Head and Neck Cancers
Role of Post-op Radiotherapy in Head and Neck Cancers
 
Sarcoma brachytherapy updates
Sarcoma brachytherapy updatesSarcoma brachytherapy updates
Sarcoma brachytherapy updates
 
Crc rt updates ethiopia
Crc rt updates   ethiopiaCrc rt updates   ethiopia
Crc rt updates ethiopia
 
Icru 71 electrons
Icru 71 electrons Icru 71 electrons
Icru 71 electrons
 
Hypofractionation in hnc
Hypofractionation in hncHypofractionation in hnc
Hypofractionation in hnc
 
Nasopharyngeal brachytherapy
Nasopharyngeal brachytherapyNasopharyngeal brachytherapy
Nasopharyngeal brachytherapy
 
Biomarkers in gliomas
Biomarkers in gliomasBiomarkers in gliomas
Biomarkers in gliomas
 
Screening in colorectal cancers dr. ashutosh
Screening in colorectal cancers  dr. ashutoshScreening in colorectal cancers  dr. ashutosh
Screening in colorectal cancers dr. ashutosh
 
Gastric cancer contouring panel discussion, icc 2017
Gastric cancer contouring panel discussion, icc 2017Gastric cancer contouring panel discussion, icc 2017
Gastric cancer contouring panel discussion, icc 2017
 
Srs debate dr. ashutosh mukherji
Srs debate   dr. ashutosh mukherjiSrs debate   dr. ashutosh mukherji
Srs debate dr. ashutosh mukherji
 
IMRT in pancreas
IMRT in pancreasIMRT in pancreas
IMRT in pancreas
 
Stomach adjuvant rt
Stomach adjuvant rtStomach adjuvant rt
Stomach adjuvant rt
 
IHC in breast CA
IHC in breast CAIHC in breast CA
IHC in breast CA
 
Radiotherapy in paediatrics - late effects and second malignancies
Radiotherapy in paediatrics - late effects and second malignanciesRadiotherapy in paediatrics - late effects and second malignancies
Radiotherapy in paediatrics - late effects and second malignancies
 
Personalised medicine in rt dr. ashutosh
Personalised medicine in rt   dr. ashutoshPersonalised medicine in rt   dr. ashutosh
Personalised medicine in rt dr. ashutosh
 

Recently uploaded

Novas diretrizes da OMS para os cuidados perinatais de mais qualidade
Novas diretrizes da OMS para os cuidados perinatais de mais qualidadeNovas diretrizes da OMS para os cuidados perinatais de mais qualidade
Novas diretrizes da OMS para os cuidados perinatais de mais qualidade
Prof. Marcus Renato de Carvalho
 
Superficial & Deep Fascia of the NECK.pptx
Superficial & Deep Fascia of the NECK.pptxSuperficial & Deep Fascia of the NECK.pptx
Superficial & Deep Fascia of the NECK.pptx
Dr. Rabia Inam Gandapore
 
Report Back from SGO 2024: What’s the Latest in Cervical Cancer?
Report Back from SGO 2024: What’s the Latest in Cervical Cancer?Report Back from SGO 2024: What’s the Latest in Cervical Cancer?
Report Back from SGO 2024: What’s the Latest in Cervical Cancer?
bkling
 
Phone Us ❤85270-49040❤ #ℂall #gIRLS In Surat By Surat @ℂall @Girls Hotel With...
Phone Us ❤85270-49040❤ #ℂall #gIRLS In Surat By Surat @ℂall @Girls Hotel With...Phone Us ❤85270-49040❤ #ℂall #gIRLS In Surat By Surat @ℂall @Girls Hotel With...
Phone Us ❤85270-49040❤ #ℂall #gIRLS In Surat By Surat @ℂall @Girls Hotel With...
Savita Shen $i11
 
Hemodialysis: Chapter 3, Dialysis Water Unit - Dr.Gawad
Hemodialysis: Chapter 3, Dialysis Water Unit - Dr.GawadHemodialysis: Chapter 3, Dialysis Water Unit - Dr.Gawad
Hemodialysis: Chapter 3, Dialysis Water Unit - Dr.Gawad
NephroTube - Dr.Gawad
 
ARTHROLOGY PPT NCISM SYLLABUS AYURVEDA STUDENTS
ARTHROLOGY PPT NCISM SYLLABUS AYURVEDA STUDENTSARTHROLOGY PPT NCISM SYLLABUS AYURVEDA STUDENTS
ARTHROLOGY PPT NCISM SYLLABUS AYURVEDA STUDENTS
Dr. Vinay Pareek
 
Triangles of Neck and Clinical Correlation by Dr. RIG.pptx
Triangles of Neck and Clinical Correlation by Dr. RIG.pptxTriangles of Neck and Clinical Correlation by Dr. RIG.pptx
Triangles of Neck and Clinical Correlation by Dr. RIG.pptx
Dr. Rabia Inam Gandapore
 
How STIs Influence the Development of Pelvic Inflammatory Disease.pptx
How STIs Influence the Development of Pelvic Inflammatory Disease.pptxHow STIs Influence the Development of Pelvic Inflammatory Disease.pptx
How STIs Influence the Development of Pelvic Inflammatory Disease.pptx
FFragrant
 
ACUTE SCROTUM.....pdf. ACUTE SCROTAL CONDITIOND
ACUTE SCROTUM.....pdf. ACUTE SCROTAL CONDITIONDACUTE SCROTUM.....pdf. ACUTE SCROTAL CONDITIOND
ACUTE SCROTUM.....pdf. ACUTE SCROTAL CONDITIOND
DR SETH JOTHAM
 
Maxilla, Mandible & Hyoid Bone & Clinical Correlations by Dr. RIG.pptx
Maxilla, Mandible & Hyoid Bone & Clinical Correlations by Dr. RIG.pptxMaxilla, Mandible & Hyoid Bone & Clinical Correlations by Dr. RIG.pptx
Maxilla, Mandible & Hyoid Bone & Clinical Correlations by Dr. RIG.pptx
Dr. Rabia Inam Gandapore
 
How to Give Better Lectures: Some Tips for Doctors
How to Give Better Lectures: Some Tips for DoctorsHow to Give Better Lectures: Some Tips for Doctors
How to Give Better Lectures: Some Tips for Doctors
LanceCatedral
 
HOT NEW PRODUCT! BIG SALES FAST SHIPPING NOW FROM CHINA!! EU KU DB BK substit...
HOT NEW PRODUCT! BIG SALES FAST SHIPPING NOW FROM CHINA!! EU KU DB BK substit...HOT NEW PRODUCT! BIG SALES FAST SHIPPING NOW FROM CHINA!! EU KU DB BK substit...
HOT NEW PRODUCT! BIG SALES FAST SHIPPING NOW FROM CHINA!! EU KU DB BK substit...
GL Anaacs
 
Pharynx and Clinical Correlations BY Dr.Rabia Inam Gandapore.pptx
Pharynx and Clinical Correlations BY Dr.Rabia Inam Gandapore.pptxPharynx and Clinical Correlations BY Dr.Rabia Inam Gandapore.pptx
Pharynx and Clinical Correlations BY Dr.Rabia Inam Gandapore.pptx
Dr. Rabia Inam Gandapore
 
NVBDCP.pptx Nation vector borne disease control program
NVBDCP.pptx Nation vector borne disease control programNVBDCP.pptx Nation vector borne disease control program
NVBDCP.pptx Nation vector borne disease control program
Sapna Thakur
 
Evaluation of antidepressant activity of clitoris ternatea in animals
Evaluation of antidepressant activity of clitoris ternatea in animalsEvaluation of antidepressant activity of clitoris ternatea in animals
Evaluation of antidepressant activity of clitoris ternatea in animals
Shweta
 
Prix Galien International 2024 Forum Program
Prix Galien International 2024 Forum ProgramPrix Galien International 2024 Forum Program
Prix Galien International 2024 Forum Program
Levi Shapiro
 
For Better Surat #ℂall #Girl Service ❤85270-49040❤ Surat #ℂall #Girls
For Better Surat #ℂall #Girl Service ❤85270-49040❤ Surat #ℂall #GirlsFor Better Surat #ℂall #Girl Service ❤85270-49040❤ Surat #ℂall #Girls
For Better Surat #ℂall #Girl Service ❤85270-49040❤ Surat #ℂall #Girls
Savita Shen $i11
 
263778731218 Abortion Clinic /Pills In Harare ,
263778731218 Abortion Clinic /Pills In Harare ,263778731218 Abortion Clinic /Pills In Harare ,
263778731218 Abortion Clinic /Pills In Harare ,
sisternakatoto
 
ANATOMY AND PHYSIOLOGY OF URINARY SYSTEM.pptx
ANATOMY AND PHYSIOLOGY OF URINARY SYSTEM.pptxANATOMY AND PHYSIOLOGY OF URINARY SYSTEM.pptx
ANATOMY AND PHYSIOLOGY OF URINARY SYSTEM.pptx
Swetaba Besh
 
basicmodesofventilation2022-220313203758.pdf
basicmodesofventilation2022-220313203758.pdfbasicmodesofventilation2022-220313203758.pdf
basicmodesofventilation2022-220313203758.pdf
aljamhori teaching hospital
 

Recently uploaded (20)

Novas diretrizes da OMS para os cuidados perinatais de mais qualidade
Novas diretrizes da OMS para os cuidados perinatais de mais qualidadeNovas diretrizes da OMS para os cuidados perinatais de mais qualidade
Novas diretrizes da OMS para os cuidados perinatais de mais qualidade
 
Superficial & Deep Fascia of the NECK.pptx
Superficial & Deep Fascia of the NECK.pptxSuperficial & Deep Fascia of the NECK.pptx
Superficial & Deep Fascia of the NECK.pptx
 
Report Back from SGO 2024: What’s the Latest in Cervical Cancer?
Report Back from SGO 2024: What’s the Latest in Cervical Cancer?Report Back from SGO 2024: What’s the Latest in Cervical Cancer?
Report Back from SGO 2024: What’s the Latest in Cervical Cancer?
 
Phone Us ❤85270-49040❤ #ℂall #gIRLS In Surat By Surat @ℂall @Girls Hotel With...
Phone Us ❤85270-49040❤ #ℂall #gIRLS In Surat By Surat @ℂall @Girls Hotel With...Phone Us ❤85270-49040❤ #ℂall #gIRLS In Surat By Surat @ℂall @Girls Hotel With...
Phone Us ❤85270-49040❤ #ℂall #gIRLS In Surat By Surat @ℂall @Girls Hotel With...
 
Hemodialysis: Chapter 3, Dialysis Water Unit - Dr.Gawad
Hemodialysis: Chapter 3, Dialysis Water Unit - Dr.GawadHemodialysis: Chapter 3, Dialysis Water Unit - Dr.Gawad
Hemodialysis: Chapter 3, Dialysis Water Unit - Dr.Gawad
 
ARTHROLOGY PPT NCISM SYLLABUS AYURVEDA STUDENTS
ARTHROLOGY PPT NCISM SYLLABUS AYURVEDA STUDENTSARTHROLOGY PPT NCISM SYLLABUS AYURVEDA STUDENTS
ARTHROLOGY PPT NCISM SYLLABUS AYURVEDA STUDENTS
 
Triangles of Neck and Clinical Correlation by Dr. RIG.pptx
Triangles of Neck and Clinical Correlation by Dr. RIG.pptxTriangles of Neck and Clinical Correlation by Dr. RIG.pptx
Triangles of Neck and Clinical Correlation by Dr. RIG.pptx
 
How STIs Influence the Development of Pelvic Inflammatory Disease.pptx
How STIs Influence the Development of Pelvic Inflammatory Disease.pptxHow STIs Influence the Development of Pelvic Inflammatory Disease.pptx
How STIs Influence the Development of Pelvic Inflammatory Disease.pptx
 
ACUTE SCROTUM.....pdf. ACUTE SCROTAL CONDITIOND
ACUTE SCROTUM.....pdf. ACUTE SCROTAL CONDITIONDACUTE SCROTUM.....pdf. ACUTE SCROTAL CONDITIOND
ACUTE SCROTUM.....pdf. ACUTE SCROTAL CONDITIOND
 
Maxilla, Mandible & Hyoid Bone & Clinical Correlations by Dr. RIG.pptx
Maxilla, Mandible & Hyoid Bone & Clinical Correlations by Dr. RIG.pptxMaxilla, Mandible & Hyoid Bone & Clinical Correlations by Dr. RIG.pptx
Maxilla, Mandible & Hyoid Bone & Clinical Correlations by Dr. RIG.pptx
 
How to Give Better Lectures: Some Tips for Doctors
How to Give Better Lectures: Some Tips for DoctorsHow to Give Better Lectures: Some Tips for Doctors
How to Give Better Lectures: Some Tips for Doctors
 
HOT NEW PRODUCT! BIG SALES FAST SHIPPING NOW FROM CHINA!! EU KU DB BK substit...
HOT NEW PRODUCT! BIG SALES FAST SHIPPING NOW FROM CHINA!! EU KU DB BK substit...HOT NEW PRODUCT! BIG SALES FAST SHIPPING NOW FROM CHINA!! EU KU DB BK substit...
HOT NEW PRODUCT! BIG SALES FAST SHIPPING NOW FROM CHINA!! EU KU DB BK substit...
 
Pharynx and Clinical Correlations BY Dr.Rabia Inam Gandapore.pptx
Pharynx and Clinical Correlations BY Dr.Rabia Inam Gandapore.pptxPharynx and Clinical Correlations BY Dr.Rabia Inam Gandapore.pptx
Pharynx and Clinical Correlations BY Dr.Rabia Inam Gandapore.pptx
 
NVBDCP.pptx Nation vector borne disease control program
NVBDCP.pptx Nation vector borne disease control programNVBDCP.pptx Nation vector borne disease control program
NVBDCP.pptx Nation vector borne disease control program
 
Evaluation of antidepressant activity of clitoris ternatea in animals
Evaluation of antidepressant activity of clitoris ternatea in animalsEvaluation of antidepressant activity of clitoris ternatea in animals
Evaluation of antidepressant activity of clitoris ternatea in animals
 
Prix Galien International 2024 Forum Program
Prix Galien International 2024 Forum ProgramPrix Galien International 2024 Forum Program
Prix Galien International 2024 Forum Program
 
For Better Surat #ℂall #Girl Service ❤85270-49040❤ Surat #ℂall #Girls
For Better Surat #ℂall #Girl Service ❤85270-49040❤ Surat #ℂall #GirlsFor Better Surat #ℂall #Girl Service ❤85270-49040❤ Surat #ℂall #Girls
For Better Surat #ℂall #Girl Service ❤85270-49040❤ Surat #ℂall #Girls
 
263778731218 Abortion Clinic /Pills In Harare ,
263778731218 Abortion Clinic /Pills In Harare ,263778731218 Abortion Clinic /Pills In Harare ,
263778731218 Abortion Clinic /Pills In Harare ,
 
ANATOMY AND PHYSIOLOGY OF URINARY SYSTEM.pptx
ANATOMY AND PHYSIOLOGY OF URINARY SYSTEM.pptxANATOMY AND PHYSIOLOGY OF URINARY SYSTEM.pptx
ANATOMY AND PHYSIOLOGY OF URINARY SYSTEM.pptx
 
basicmodesofventilation2022-220313203758.pdf
basicmodesofventilation2022-220313203758.pdfbasicmodesofventilation2022-220313203758.pdf
basicmodesofventilation2022-220313203758.pdf
 

Lung plan evaluation

  • 1. Plan evaluation: Lung Cancers Dr. Ashutosh Mukherji Additional Professor, Department of Radiotherapy, Regional Cancer Centre, and Associate Dean (Research), JIPMER
  • 2. Target Volumes • Radiotherapy alone affords intrathoracic control in up to 50% of NSCLC cases, provided a total dose > 60 Gy is employed • For many years, standard RT practice was: – 40 to 50 Gy to the electively irradiated regional-nodal areas – Additional 10-20 Gy delivered to the primary tumor through reduced fields.
  • 3. Lung cancer radiotherapy • RT for lung cancer getting increasingly sophisticated • Usually addition of concurrent chemotherapy in radical treatment of locally advanced tumours • Side effects tend to increase with poor lung function patients and addition of chemotherapy. • Need to identify parameters to preempt / reduce toxicity • V 20 and V 5 are two such parameters
  • 4. RT-Planning – Definition of Target Volumes ICRU 50 + 62 Gross Tumour Volume Clinical Target Volume Planning Target Volume CT: standard imaging modality Complementary information by MRI and PET scanning Limiting factors of CT imaging for lung cancer: -planning-CT without intravenous contrast so as not to disturb the electron density information interpretation always in conjunction with diagnostic CT -not routinely possible to distinguish T3 – T4 (MRI some advantages) -MRI used for imaging apical primary tumours (Pancoast) -Sensitivity / specificity only 60 / 77% for LN knowledge of normal anatomy (LN levels, hilar anatomy) ! knowledge of patterns of lymphatic drainage
  • 5. RT-Planning – Defining the GTV Integrating PET Value of PET for PT: Atelectasis – reduction of irradiated volume Value of PET for LN staging: Sensitivity 79% Specificity 91% Negative predictive value 95% Positive predictive value 80% (hot spots still require verification) Value of PET for Metastases: metastases detected in10-15% of surgical candidates Impact of PET on RT planning PTV increased in 64% (detected nodes) decreased in 36% (exclusion of atelectasis) (Erdi 2002) Average reduction of PTV by 29% Average reduction of V20 by 27% (Vanuytsel 2000) Interobserver variability reduced: mean ratio of GTV without PET: 2.31 mean ratio of GTV with PET: 1.56 (Caldwell 2001)
  • 6. RT-Planning – Defining the GTV Impact of PET: PTV
  • 7. RT-Planning – Defining the GTV Limiting factors of PET -Resolution 4-8mm (depending on scanner and institution) -Registration errors (esp. with software based fusion) -Threshold value (SUV) individually to be determined Summary: PET is a promising complementary tool in RT planning of NSCLC. Its value for staging has been established and preliminary reports suggest that it may lead to more consistent definition of GTV in RT planning. However, it is still not clear, whether this will translate into better survival.
  • 8. RT-Planning – Defining the CTV 1. Margin around primary tumour (microscopic spread) Histopathologic quantification of subclinical cancer around the grossly visible primary (Giraud 2000): Microscopic extension Adeno Squamos mean value 2.69mm 1.48mm 5mm margin covers: 80% 91% margin to cover 95% 8mm 6mm This data could also be used for IMRT planning: -define constraint for GTV (dose escalation to primary) -define constraint for subclinical disease (less dose) -increase therapeutic index
  • 9. RT-Planning – Defining the CTV 2. Subclinical lymph nodes (ENI) -high risk of nodal spread in lung cancer -but value of ENI is not proven Reasons against ENI: -less than 20% locally controlled 1y after RT with conventional dose (Arriagada 1991) -need for more intense treatment to gross tumour -large volumes prevent dose escalation (normal tissue tolerance) -small primary tumor and small total tumor volume predictive (Basaki 2006, RTOG 93-11 2008) -modern chemotherapy regimens may lead to better control of microscopic disease
  • 10. ?? Elective Nodal Irradiation ?? • The rationale against elective nodal irradiation is the high local recurrence rates and the high chance of distant metastasis. • A series of 171 patients treated definitively with 3DCRT to only involved field volumes. • 6.4% of patients suffered elective nodal failures
  • 11. Why the less than expected nodal recurrence? • Incidental doses to the ipsilateral hilum, paratracheal, and subcarinal nodes approach 40 to 50 Gy • Patients may die of local failure, distant failure, or intercurrent illness without detection of elective nodal failures.
  • 12. RT-Planning – Defining the CTV 2. Subclinical lymph nodes (ENI) From large .... “Old“ Standard … (Perez 1997)
  • 13. RT-Planning – Defining the CTV 2. Subclinical lymph nodes (ENI) .... to small ! …“New“ Trend (IMRT 2007)
  • 14. RT-Planning – Defining the PTV ICRU recommendations CTV ... + Internal Margin (Internal Target Volume) variations in position, size and shape of CTV (internal reference system attached to the patient) + Set-up Margin variations in relation patient - beam (external reference system attached to machine)
  • 15. RT-Planning – Defining the PTV Reducing set-up uncertainty: -Daily EPID: -matching DRR - EPI -distinguish between systematic (needs correction) and random error (no correction needed)
  • 16. RT-Planning – Defining the PTV Reducing respiration induced errors: Size of movement dependent on: - tumour location in the lung - fixation to adjacent structures - lung capacity and oxygenation - patient fixation and anxiety Steppenwoolde 2004 Reducing respiration induced errors: -Breath - hold -Voluntary (Deep Inspiration Breath Hold) -Forced (Active Breathing Control) -CT scanning -Slow scanning -Respiration correlated CT -Gating Average movement in normal breathing: - Upper lobe 0 - 0.5cm - Lower lobe 1.5 - 4.0cm - Middle lobe 0.5 - 2.5cm - Hilum 1.0 - 1.5cm
  • 17. RT-Planning – Defining the PTV Reducing respiration induced errors: Gated CT normally reduces the margin PTV - CTV (compared to using published data):
  • 18. RT-Planning – Defining the PTV Drawing PTV in gated planning CT: -Define GTV/CTV for inspiration and expiration phase -Give a margin of 0.5 - 1cm in all directions (setup uncertainty) DON’T use dose escalation and highly conformal techniques such as IMRT for lung cancer until tumour motion can be taken into account ! In the meantime ... -Outline GTV as best as possible -Construct CTV based on the literature -Construct PTV based on measured tumour motion and known setup uncertainty.
  • 19. ERS 2009 19 The risk of developing radiation pneumonitis-induced lung toxicity can be estimated by calculating the dose– volume histogram of the lungs, including V20 and mean lung dose (MLD)
  • 20. V 20 “V20” Percentage of the lung volume which receives radiation doses of 20 Gy or more. (with subtraction of the vol involved by lung cancer - PTV) The risk for radiation pneumonitis depends on V20 V20 = 22% risk for radiation pneumonitis is nearly zero. V 20 = 33% radiation induced pneumonitis is 10 -15% V20 of 35%, 40% - radiation pneumonitis nearly 50%.
  • 21. PhaseI/II Stage 1-3 unresectable 3DCRT, 2.15Gy fr Group1 V20Gy<25%: 70.9Gy/33frs to 90.3Gy/42frs Group2 V20Gy – 25-36%: 70.9Gy/33frs to 77.4Gy/36frs Group 3: V20>37% Closed early RTOG 9311: Trial Schema 179 pts
  • 22. RTOG 9311 : Conclusions • RT dose was safely escalated using the 3D CRT • 83.8 Gy for pts with V20 values of <25% Grp I, • 77.4 Gy for pts with V20 values 25% - 36% Grp 2, • The 90.3 Gy dose was too toxic (deaths 2 pts) • Using fraction size of 2.15 Gy. • Elective nodal failure occurred in <10 pts Jafrey Badley IJRBP vol 61, No 2, 318-328, 2005
  • 23. Volumes while contouring lung as OAR • Need to select the optimal CT window settings (Lung window) • W = 1600 and C=-600 for parenchyma • Contour each lung separately • Contour GTV, CTV and PTV • Using Boolean function , generate lung OAR • Lung OAR= (Left lung + Right Lung) - PTV
  • 25. Basic Definitions • V 20 = Volume of (B/L lung – PTV) receiving 20 Gray OR MORE Total volume of B/L Lung – PTV (represents intermediate dose area) • V 5 = Volume of (B/L lung – PTV) receiving 5 Gray OR MORE Total volume of B/L Lung – PTV (represents low dose area) Normal tissue constraints for Lung V 20 <35% V 5 < 60%
  • 26. V 5 • Represents area of lung receiving low /very low dose RT • Gained in importance in IMRT era • Especially important in techniques such as VMAT and Tomotherapy which give rotational therapies • Another way to emphasising that low dose areas with IMRT are as equally important.
  • 27. 27 V5
  • 28. 28 V5 opposite lung V5 treated lung
  • 29. Seminal Publication – V 20 Graham MV, Purdy JA, Emami B, et al. Clinical dose- volume histogram analysis for pneumonitis after 3D treatment for non-smallcell lung cancer (NSCLC). Int J Radiat Oncol Biol Phys 1999;45:323-329.
  • 31. 31 V20 opposite lung V20 treated lung
  • 32. Elevated V 20 and V 5 • Truly elevated V 20 and V 5 – Large PTV – Poor planning • Spurious elevation of V 20 and V 5 – Lung not contoured properly (portions left out) – Incorrect window used – PTV not subtracted out from bilateral lungs
  • 33. Means to reduce V 20 (3D CRT) – Need to have a good measure of tumour location and likely volumes – Lower lobe tumours likely to have worse dosimetric parameters – Need to place appropriate beams(beam angles, number) – Special arrangements in specific tumour positions
  • 34. Means to reduce V 20 • Use IMRT instead of 3 DCRT in appropriate cases • Use of advanced strategies like gating/tracking/breath hold (it shall decrease the PTV and thereby decrease the zone that get 20 Gray) • Use of ABC device – PTV smaller – Simulation and treatment in inspiratory position – Lungs inflated – Lung volume increases and hence denominator more, V 20 falls
  • 35.
  • 36. • 41 patients of NSCLC • 3 D CRT and IMRT plans(9 F, equidistant, coplanar, generated) • Target, isocentre and prescription same as 3 D CRT Murshed, IJROBP, 2003V 10 and V20 reduced by 7% and 10% respectively
  • 37. IGRT- 4 D aspects • Further ensuring the Planned dose and the treatment dose similarity • Removal of motion encompassing margins may reduce normal tissue dose • Reduction in normal tissue dose may facilitate tumour dose escalation • Higher doses delivered to the tumour could result in an improved cure rate Individualised Motion Margin Setup & Equipment Margins Clinical Target Volume Planning Target Volume Residual Error Margins Clinical Target Volume Target tracking Treatments
  • 38. Conventional With gated imaging Effect of Gated/4 D imaging Tumor Keall et al Aust Phys Eng Sci Med 2002
  • 39. ABC • Device holds the patients breath in a particular phase of respiration • Usually the mDIBH level chosen – 70%to 80% of maximum inspiratory capacity • Suitable breath hold duration chosen – commonly 20 to 25 seconds
  • 40. ABC • CT scan acquired (approx two breath holds required to scan the thorax/breast area) • Treatment planning and execution(4-6 breath holds per treatment)
  • 41. ABC outcomes • 18 NSCLC patients from RMH , UK • Mean reduction in GTV 25% (p= 0.003). • Compared with free-breathing, ABC reduced • V(20) by 13% (p=0.0001) • V(13) by 12% (p=0.001) • MLD by 13% (p<0.001) Brada et al IJROBP 2010
  • 42. Outcomes of Respiratory Gating • Twenty patients with CT under assisted breath hold at normal inspiration, at full expiration and under free breathing • 13 of 20 patients had GTVs of <100 cm3 • Benefit of V20 reduction only with small tumours (volume of GTV < 100 cm3) and significant tumour motion Starkschall IJROBP 2004
  • 43. Caution! • V20 and V5 could vary from one planning workstation to another • Different algorithms may yield variable V 20 and V 5 (Batho, Monte Carlo algorithm) • Algorithms can be especially important as there is variation in lung density. • Algorithms derived directly from Monte Carlo, such as superposition-convolution and collapsed cone far superior to algorithms of the past (e.g. the one used in seminal publication)
  • 44. Drawbacks of V 20/ V 5 • DVH represents anatomic pulmonary volume, which does not reflect a variety of confounding factors. • Not a functional parameter (does not take into account lung function) • Several other factors important in radiation pneumonitis and need to be accounted (PS,concurrent chemo, smoking, age, ….)
  • 45. 45 V30 opposite lung V30 treated lung
  • 46. 46 Global Dmax location Target volume Dmax location Vdmax
  • 47. QA…… Fluence analyses showed most planned cases treatable with ≥ 95% fidelity 47
  • 48. Summary / Conclusions • V 5 and V 20 are important parameters to see and evaluate during radical radiotherapy of lung cancer • V30 and VDmax also need to be seen. • For IMRT plans PTV cover and contouring should take into account tumour movement • Be cognizant of the pitfalls of these parameters as well • See totality of patient / tumour / dosimetric parameters and not one or two factors in isolation
  • 49. Summary planning Recommendations - EORTC • 3-D radiotherapy planning is essential for ensuring optimal both target coverage and the sparing of normal tissues. • 3D margins for the PTV based on institutional random and systematic errors and tumour movement • Margins required for microscopic tumour extension in radiotherapy planning of NSCLC are approximately 5-6 mm. • Risk of radiation pneumonitis can be estimated from the V20 (volume of both lungs minus the PTV which receives a dose of 20 Gy), and by the mean lung dose. • Incorporating FDG-PET findings into CT-based planning scan results in changes to radiotherapy plans in a significant proportion of patients. 49
  • 50.